The Gold Coast criteria increases the diagnostic sensitivity for amyotrophic lateral sclerosis in a Chinese population.
Amyotrophic lateral sclerosis
Diagnostic criteria
Gold Coast
Sensitivity
Journal
Translational neurodegeneration
ISSN: 2047-9158
Titre abrégé: Transl Neurodegener
Pays: England
ID NLM: 101591861
Informations de publication
Date de publication:
09 08 2021
09 08 2021
Historique:
received:
25
05
2021
accepted:
20
07
2021
entrez:
10
8
2021
pubmed:
11
8
2021
medline:
29
1
2022
Statut:
epublish
Résumé
The aim of this study was to assess and compare the diagnostic utility of a new diagnostic criteria for amyotrophic lateral sclerosis (ALS), abbreviated as the 'Gold Coast Criteria', with the revised El Escorial (rEEC) and Awaji criteria. Clinical and electrophysiological data of 1185 patients from January 2014 to December 2019 in the Peking Union Medical College Hospital ALS database were reviewed. The sensitivity of the Gold Coast criteria was compared to that of the possible rEEC and Awaji criteria (defined by the proportion of patients categorized as definite, probable, or possible ALS). A final diagnosis of ALS was recorded in 1162 patients. The sensitivity of the Gold Coast criteria (96.6%, 95% confidence interval [CI] = 95.3%-97.5%) was greater than that of the rEEC (85.1%, 95%CI = 82.9%-87.1%) and Awaji (85.3%, 95%CI = 83.2%-87.3%). In addition, the sensitivity of the novel criteria maintained robust across subgroups, and the advantage was more prominent in limb-onset ALS patients and those who completed electromyographic tests. In those who did not achieve any of the rEEC diagnostic categories, the sensitivity of Gold Coast criteria was 84.4%. The current study demonstrated that the Gold Coast criteria exhibited greater diagnostic sensitivity than the rEEC and Awaji criteria in a Chinese ALS population. The application of the Gold Coast criteria should be considered in clinical practice and future therapeutic trials.
Identifiants
pubmed: 34372918
doi: 10.1186/s40035-021-00253-2
pii: 10.1186/s40035-021-00253-2
pmc: PMC8351337
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
28Informations de copyright
© 2021. The Author(s).
Références
J Neurol Neurosurg Psychiatry. 2010 Jun;81(6):646-9
pubmed: 20522872
PLoS One. 2017 Mar 1;12(3):e0171522
pubmed: 28249004
J Neurol Sci. 2006 Dec 1;250(1-2):45-9
pubmed: 16920152
Acta Neurol Scand. 2014 Mar;129(3):163-7
pubmed: 23819875
Amyotroph Lateral Scler Other Motor Neuron Disord. 2000 Dec;1(5):293-9
pubmed: 11464847
Clin Neurophysiol. 2012 Feb;123(2):382-5
pubmed: 21764635
Clin Neurophysiol. 2019 Feb;130(2):307-314
pubmed: 30573424
Neurology. 2016 Aug 16;87(7):684-90
pubmed: 27440148
Amyotroph Lateral Scler. 2009 Feb;10(1):53-7
pubmed: 18985466
Clin Neurophysiol. 2020 Aug;131(8):1962-1963
pubmed: 32418823
Neurology. 2002 Jul 9;59(1):99-103
pubmed: 12105314
J Neurol Sci. 2011 Mar 15;302(1-2):29-32
pubmed: 21215419
Ann Neurol. 2021 May;89(5):979-986
pubmed: 33565111
Clin Neurophysiol. 2020 Aug;131(8):1767-1768
pubmed: 32504937
Clin Neurophysiol. 2018 May;129(5):926-930
pubmed: 29550653
Amyotroph Lateral Scler. 2010 Dec;11(6):497-501
pubmed: 20536375
Clin Neurophysiol. 2008 Mar;119(3):497-503
pubmed: 18164242
BMJ Open. 2014 May 14;4(5):e005213
pubmed: 24833696
Muscle Nerve. 2012 Feb;45(2):175-82
pubmed: 22246871
J Neurol Neurosurg Psychiatry. 2016 Aug;87(8):821-30
pubmed: 27093948
Muscle Nerve. 2015 Jun;51(6):822-9
pubmed: 25597926
Muscle Nerve. 2010 Feb;41(2):161-5
pubmed: 20082312
Arch Neurol. 2012 Nov;69(11):1410-6
pubmed: 22892641
Amyotroph Lateral Scler Frontotemporal Degener. 2016 Oct - Nov;17(7-8):610-613
pubmed: 27348463
Neurology. 2003 Apr 22;60(8):1252-8
pubmed: 12707426
Ann Neurol. 2011 Jul;70(1):79-83
pubmed: 21437935
Arch Neurol. 2000 Aug;57(8):1171-6
pubmed: 10927797
Clin Neurophysiol. 2020 Aug;131(8):1975-1978
pubmed: 32387049